Introduction: Pancreatic cancer is a major health problem because of its aggressiveness and the lack of effective systemic therapies. The aim of the study was the identification of beneficial properties of combined celecoxib and capecitabine treatment during an experimental pancreatic cancer model. Methods: N-nitrosobis (2-oxopropyl)amine (BOP) was used as a tumoral agent for 12 weeks. Celecoxib and capecitabine were administered either as monotherapy or combined 12 weeks after cancer induction for a period of 24 weeks. The presence of well-developed or moderate adenocarcinoma was evaluated in the pancreas. Several markers of stress, such as lipoperoxides, reduced glutathione (GSH), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GHS-Px) were determined. Results: BOP induced the presence of pancreatic tumors associated with a rise in lipoperoxides and the reduction of the antioxidant status in the pancreas. The administration of celecoxib and capecitabine reduced the number of animals with tumors (33 and 66%, respectively). This antitumoral effect was associated with a recovery of GSH, SOD and CAT activity in the pancreas of BOP-treated animals. The combined treatment exerted a synergic antitumoral effect and reduced pancreatic oxidative stress. Conclusion: The combined administration of celecoxib and capecitabine exerted a synergistic antitumoral effect and increased the antioxidant status restoration in pancreatic cancer.

Keywords:
Celecoxib, Capecitabine, Adenocarcinoma, Oxidative stress
1.
Beger HG, Rau B, Gansauge F, Poch B, Link KH: Treatment of pancreatic cancer: challenge of the facts. World J Surg 2003;27:1075–1084.
2.
Yeo CJ, Cameron JL, Sohn TA: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248–260.
3.
Iacobuzio-Donahue CA, Hruban RH: Gene expression in neoplasms of the pancreas: applications to diagnostic pathology. Adv Anat Pathol 2003;10:125–134.
4.
Bockman DE, Guo J, Büchler P, Müller MW, Bergmann F, Friess H: Origin and development of the precursor lesions in experimental pancreatic cancer in rats. Lab Invest 2003;83:853–859.
5.
Stadtman RE: Protein oxidation and aging. Science 1992;245:1220–1224.
6.
Termini J: Hydroperoxide-induced DNA damage and mutations, Mutation Res 2000;45:107–124.
7.
Marnett LJ: Oxyradicals and DNA damage. Carcinogenesis 2000;21:361–370.
8.
Burcham PC: Genotoxic lipid peroxidation products: their DNA-damaging properties and role in formation of endogenous DNA adducts. Mutagenesis 1998;13:287–305.
9.
Parikh AA, Liu WB, Fan F: Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer 2003;98:4.
10.
Korc M: Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2003,2:8.
11.
Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K: Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004;64:2030–2038.
12.
Bakhle YS: COX-2 and cancer: a new approach to an old problem. Br J Pharmacol 2001;134:1137–1150.
13.
Raut CP, Nawrocki S, Lashinger LM, Davis DW, Khanbolooki S, Xiong H, Ellis LM, McConkey DJ: Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis. Cancer Biol Ther 2004;3:1217–1224.
14.
Blanke C: Role of COX-2 inhibitors in cancer therapy. Cancer Invest 2004;22:271–282.
15.
Jimeno A, Amador ML, Kulesza P, Wang X, Rubio-Viqueira B, Zhang X, Chan A, Wheelhouse J, Kuramochi H, Tanaka K, Danenberg K, Messersmith WA, Almuete V, Hruban RH, Maitra A, Yeo CJ, Hidalgo M: Assessment of celecoxib pharmacodynamics in pancreatic cancer. Mol Cancer Ther 2006;5:3240–3247.
16.
Nair P, Kanwar SS, Sanyal SN: Effects of non steroidal anti-inflammatory drugs on the antioxidant defense system and the membrane functions in the rat intestine. Nutr Hosp 2006;21:638–649.
17.
Ozturk H, Gezici A, Ozturk H: The effect of celecoxib, a selective COX-2 inhibitor, on liver ischemia/reperfusion-induced oxidative stress in rats. Hepatol Res 2006;34:76–83.
18.
Matthias C, Schuster MT, Zieger S, Harreus U: COX-2 inhibitors celecoxib and rofecoxib prevent oxidative DNA fragmentation. Anticancer Res 2006;26:2003–2007.
19.
Milella M, Gelibter A, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Malaguti P, Pellicciotta M, Terzoli E, Cognetti F: Pilot Study of celecoxib and infusional 5-FU as a second line treatment for advanced pancreatic carcinoma. Cancer 2004;101:133–138.
20.
Smith DB, Neoptolemos JP: Capecitabine in carcinoma of the pancreas. Expert Opin Pharmacother 2006;7:1633–1639.
21.
Cartwright TH, Cohn A, Varkey JA: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20:160–164.
22.
Hess V, Salzberg M, Borner M: Combining capecitabine and gemcitabine in a patient with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2003;21:66–68.
23.
Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212–2217.
24.
Sultana A, Ghaneh P, Cunningham D, Starling N, Neoptolemos JP, Smith CT: Gemcitabine-based combination chemotherapy in advanced pancreatic cancer – indirect comparison. BMC Cancer 2008;8:192.
25.
Boeck S, Hoehler T, Seipelt G, et al: Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 2008;19:340–347.
26.
Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS: Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007;25:4787–4792.
27.
Roy S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman D, Diasio RB: Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J 2007;13:247–256.
28.
McGinn CJ, Chang AE, Colletti LM, Normolle DP, Hejna GF, Lawrence TS, Zalupski MM: Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005;63:1325–1330.
29.
Ben-Josef E, Shields AF, Vaishampayan U, Vaitkevicius V, El-Rayes BF, McDermott P, Burmeister J, Bossenberger T, Philip PA: Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.Int J Radiat Oncol Biol Phys 2004;59:454–459.
30.
Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, Guba S, Andrade R, Chabot J: The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 2008;61:177.
31.
Hissin PJ, Hilf R: A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 1976;74:214–226.
32.
Sun Y, Oberley LW, Li Y: A simple method for clinical assay of superoxide dismutase. Clin Chem 1988;34:479–500.
33.
Aebi H: Catalase in vitro. Methods Enzymol 1984;105:121–126.
34.
Flohé L, Gunzler WA: Assays of glutathione peroxidase. Methods Enzymol 1984;105:114–121.
35.
Wenger FA, Kilian M, Ridders J, Stahlknecht P, Schimke I, Guski H, Jacobi CA, Müller JM: Influence of antioxidative vitamins A, C and E on lipid peroxidation in BOP-induced pancreatic cancer in Syrian hamsters. Prostagland Leukot Fatty Acids 2001;65:165–171.
36.
Wenger FA, Kilian M, Jacobi CA, Mautsch I, Peter FJ, Guski H: Effects of octreotide on liver metastasis and intrametastatic lipid peroxidation in experimental pancreatic cancer. Oncology 2001;60:282–288.
37.
Wenger FA, Kilian M, Achucarro P, Heinicken D, Schimke I, Guski H, Jacobi CA, Müller JM. Effects of celebrex and zyflo on BOP-induced pancreatic cancer in Syrian hamsters. Pancreatology 2002;2:54–60.
38.
Ruiz-Rabelo JF, Vázquez R, Perea MD, Cruz A, González R, Romero A, Muñoz-Villanueva MC, Túnez I, Montilla P, Muntané J, Padillo FJ: Beneficial properties of melatonin in an experimental model of pancreatic cancer. J Pineal Res 2007;43:270–275.
39.
Pour P, Althoff J, Krüger FW, Mohr U: A potent pancreatic carcinogen in Syrian golden hamster: N-nitroso-bis(2-oxopropyl)amine. J Natl Cancer Inst 1977;58:1449–1453.
40.
Wenger FA, Killian M, Mautsch I, Jacobi CA, Schimke I, Saul GJ, Guski H, Müller JM: Influence of octreotide and tamoxifen on tumor growth and liver metastasis in N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian hamsters. Horm Res 2000;54:74–77.
41.
Gingell R, Wallcave L, Nagel D, Kupper R, Pour P: Metabolism of the pancreatic carcinogens N-nitroso-bis(2-oxopropyl)amine and N-nitroso-bis(2-hydroxypropyl) amine in the Syrian hamster. J Natl Cancer Inst 1976;57:1175–1178.
42.
Pour PM, Runge RG, Birt D, Gingell R, Lawson T, Nagel D, Wallave L, Salamsi SZ: Current knowledge of pancreatic carcinogenesis in the hamster and its relevance to the human disease. Cancer 1981;47:1573–1587.
43.
Saif MW, Kang SP, Ledbetter L, Steg A, Diasio R, Johnson M: Long-term survival on capecitabine in two gemcitabine-refractory pancreatic cancer patients: is there a pharmacogenetic explanation? J Pancreas 2007;8:799–805.
44.
Saif MW, Diasio R: Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clin Colorectal Cancer 2006;5:359–362.
45.
Saif MW, Moody JS, Russo SM: Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer. JOP 2005;6:325–333.
46.
Schuller J, Cassidy J, Dumont E: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291–297.
47.
Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxigenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–1952.
48.
Kawamori T, Rao CV, Seibert K, Reddy BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409–412.
49.
Yip-Schneider MT, Wu H, Njoku V, Ralstin M, Holcomb B, Crooks PA, Neelakantan S, Sweeney CJ, Schmidt CM: Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. Pancreas 2008;37:45–53.
50.
Colby JK, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, Kawamoto T, Penny K. Riggs, Pavone AI, Sawicki J, Fischer SM: Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia 2008;10:782–796.
51.
Furukawa F, Nishikawa A, Lee IS, Kanki K, Umemura T, Okazaki K, Kawamori T, Wakabayashi K, Hirose M: A cyclooxygenase- 2 inhibitor, nimesulide, inhibits post-initiation phase of nitrosobis (2-oxopropyl) amine-induced pancreatic carcinogenesis in hamsters. Int J Cancer 2003;104:269–273.
52.
D’Andrea GM: Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 2005;55:319–321.
53.
Conklin KA: Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 2004;3:294–300.
54.
Block KI, Koch AC, Mead MD, Tothy PK, Newman RA, Gyllenhaal C: Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. Cancer Treat Rev 2007;33:407–418.
55.
Blanquicett C, Saif W, Buchsbaum D, Eloubeidi M, Vickers S, Chhieng D, Carpenter M, Sellers J, Russo S, Diasio R, Johnson M: Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res 2005;11:8773–8781.
© 2010 S. Karger AG, Basel and IAP
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.